JP2017530163A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017530163A5 JP2017530163A5 JP2017518197A JP2017518197A JP2017530163A5 JP 2017530163 A5 JP2017530163 A5 JP 2017530163A5 JP 2017518197 A JP2017518197 A JP 2017518197A JP 2017518197 A JP2017518197 A JP 2017518197A JP 2017530163 A5 JP2017530163 A5 JP 2017530163A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- chemokine receptor
- blocking antibody
- ccr9 inhibitor
- receptor ccr9
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100022718 Atypical chemokine receptor 2 Human genes 0.000 claims 19
- 239000003112 inhibitor Substances 0.000 claims 19
- 108010089833 chemokine receptor D6 Proteins 0.000 claims 18
- 230000000903 blocking effect Effects 0.000 claims 16
- 102000006495 integrins Human genes 0.000 claims 16
- 108010044426 integrins Proteins 0.000 claims 16
- 150000001875 compounds Chemical class 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 229960004914 vedolizumab Drugs 0.000 claims 6
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 5
- 241000124008 Mammalia Species 0.000 claims 4
- 229960000106 biosimilars Drugs 0.000 claims 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 150000001204 N-oxides Chemical class 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 102000019034 Chemokines Human genes 0.000 claims 1
- 108010012236 Chemokines Proteins 0.000 claims 1
- 101000678892 Homo sapiens Atypical chemokine receptor 2 Proteins 0.000 claims 1
- 101000716070 Homo sapiens C-C chemokine receptor type 9 Proteins 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 0 CC(*)(*)c1cc(NC)c(C)cc1 Chemical compound CC(*)(*)c1cc(NC)c(C)cc1 0.000 description 16
- DCKWJSZXJQJRDV-UHFFFAOYSA-N CC(C)(C)c(c(F)c1)ccc1S(Nc1cc(C)n[n]1-c1c(ccc(N)n2)c2ccc1)(=O)=O Chemical compound CC(C)(C)c(c(F)c1)ccc1S(Nc1cc(C)n[n]1-c1c(ccc(N)n2)c2ccc1)(=O)=O DCKWJSZXJQJRDV-UHFFFAOYSA-N 0.000 description 2
- APTYKFYFUUVOHG-UHFFFAOYSA-N CC(C)(C)c(c(F)c1)ccc1S(Nc1cc(C)n[n]1-c(c1c2nccc1)ccc2OC)(=O)=O Chemical compound CC(C)(C)c(c(F)c1)ccc1S(Nc1cc(C)n[n]1-c(c1c2nccc1)ccc2OC)(=O)=O APTYKFYFUUVOHG-UHFFFAOYSA-N 0.000 description 1
- HHPCSQXABZSQHW-UHFFFAOYSA-N CC(C)(C)c(c(F)c1)ccc1S(Nc1cc(CF)n[n]1-c1c(cccn2)c2ccc1)(=O)=O Chemical compound CC(C)(C)c(c(F)c1)ccc1S(Nc1cc(CF)n[n]1-c1c(cccn2)c2ccc1)(=O)=O HHPCSQXABZSQHW-UHFFFAOYSA-N 0.000 description 1
- SFRLVHVJBPMQIY-AXXAPAIGSA-O CC(C)(C)c(cc1)ccc1S(N/C(/Nc1c(ccc(N)n2)c2ccc1)=C/C(C)=[NH2+])(=O)=O Chemical compound CC(C)(C)c(cc1)ccc1S(N/C(/Nc1c(ccc(N)n2)c2ccc1)=C/C(C)=[NH2+])(=O)=O SFRLVHVJBPMQIY-AXXAPAIGSA-O 0.000 description 1
- SIJACDPXYMLODQ-HTTCRTGESA-O CC(C)(C)c(cc1)ccc1S(N/C(/Nc1c(cccc2)c2ncc1)=C/C(C)=[NH2+])(=O)=O Chemical compound CC(C)(C)c(cc1)ccc1S(N/C(/Nc1c(cccc2)c2ncc1)=C/C(C)=[NH2+])(=O)=O SIJACDPXYMLODQ-HTTCRTGESA-O 0.000 description 1
- PSOIELJEPMNOLE-QKNIHMACSA-N CC(C)(C)c(cc1)ccc1S(N/C(/Nc1c(cccn2)c2ccc1)=C/C(C#N)=N)(=O)=O Chemical compound CC(C)(C)c(cc1)ccc1S(N/C(/Nc1c(cccn2)c2ccc1)=C/C(C#N)=N)(=O)=O PSOIELJEPMNOLE-QKNIHMACSA-N 0.000 description 1
- WHLJLEYBVHKFFP-PCVVEWSSSA-O CC(C)(C)c(cc1)ccc1S(N/C(/Nc1c(cccn2)c2ccc1)=C/C(COC)=[NH2+])(=O)=O Chemical compound CC(C)(C)c(cc1)ccc1S(N/C(/Nc1c(cccn2)c2ccc1)=C/C(COC)=[NH2+])(=O)=O WHLJLEYBVHKFFP-PCVVEWSSSA-O 0.000 description 1
- UHVHSTNMWBLETJ-PJPHTRBISA-O CC(C)(C)c(cc1)ccc1S(N/C(/Nc1c(ccnc2)c2ccn1)=C/C(C)=[NH2+])(=O)=O Chemical compound CC(C)(C)c(cc1)ccc1S(N/C(/Nc1c(ccnc2)c2ccn1)=C/C(C)=[NH2+])(=O)=O UHVHSTNMWBLETJ-PJPHTRBISA-O 0.000 description 1
- QNKZFAFQMCDIBN-UHFFFAOYSA-N CC(C)(C)c(cc1)ccc1S(Nc1cc(C(F)(F)F)n[n]1-c1c(cccn2)c2ccc1)(=O)=O Chemical compound CC(C)(C)c(cc1)ccc1S(Nc1cc(C(F)(F)F)n[n]1-c1c(cccn2)c2ccc1)(=O)=O QNKZFAFQMCDIBN-UHFFFAOYSA-N 0.000 description 1
- MUTDAHYJEMYSNM-UHFFFAOYSA-N CC(C)(C)c(cc1)ccc1S(Nc1cc(C(F)F)n[n]1-c1c(cccn2)c2ccc1)(=O)=O Chemical compound CC(C)(C)c(cc1)ccc1S(Nc1cc(C(F)F)n[n]1-c1c(cccn2)c2ccc1)(=O)=O MUTDAHYJEMYSNM-UHFFFAOYSA-N 0.000 description 1
- MTKYXKITZAKQIQ-UHFFFAOYSA-N CC(C)(C)c(cc1)ccc1S(Nc1cc(C)n[n]1-c(cc1)c(cccn2)c2c1Cl)(=O)=O Chemical compound CC(C)(C)c(cc1)ccc1S(Nc1cc(C)n[n]1-c(cc1)c(cccn2)c2c1Cl)(=O)=O MTKYXKITZAKQIQ-UHFFFAOYSA-N 0.000 description 1
- KURMWISZLWGOHG-UHFFFAOYSA-N CC(C)(C)c(cc1)ccc1S(Nc1cc(C)n[n]1-c(nc1)c(cccc2)c2c1Cl)(=O)=O Chemical compound CC(C)(C)c(cc1)ccc1S(Nc1cc(C)n[n]1-c(nc1)c(cccc2)c2c1Cl)(=O)=O KURMWISZLWGOHG-UHFFFAOYSA-N 0.000 description 1
- FVRGRVDZBHHPQX-UHFFFAOYSA-N CC(C)(C)c(cc1)ccc1S(Nc1cc(C)n[n]1-c1c(ccc(F)c2)c2ncc1)(=O)=O Chemical compound CC(C)(C)c(cc1)ccc1S(Nc1cc(C)n[n]1-c1c(ccc(F)c2)c2ncc1)(=O)=O FVRGRVDZBHHPQX-UHFFFAOYSA-N 0.000 description 1
- HKZQZKCDOFEUAP-UHFFFAOYSA-O CC(C)(C)c(cc1)ccc1S(Nc1cc(C)n[n]1-c1c(ccc[nH+]2)c2ccc1)(=O)=O Chemical compound CC(C)(C)c(cc1)ccc1S(Nc1cc(C)n[n]1-c1c(ccc[nH+]2)c2ccc1)(=O)=O HKZQZKCDOFEUAP-UHFFFAOYSA-O 0.000 description 1
- KCHWPVBTBMEOSM-UHFFFAOYSA-N CC(C)(C)c(cc1)ccc1S(Nc1cc(C)n[n]1-c1c(cccc2)c2c(N)nc1)(=O)=O Chemical compound CC(C)(C)c(cc1)ccc1S(Nc1cc(C)n[n]1-c1c(cccc2)c2c(N)nc1)(=O)=O KCHWPVBTBMEOSM-UHFFFAOYSA-N 0.000 description 1
- IXEPFVNCVWAELZ-UHFFFAOYSA-N CC(C)(C)c(cc1)ccc1S(Nc1cc(C)n[n]1-c1c(cccc2)c2ccn1)(=O)=O Chemical compound CC(C)(C)c(cc1)ccc1S(Nc1cc(C)n[n]1-c1c(cccc2)c2ccn1)(=O)=O IXEPFVNCVWAELZ-UHFFFAOYSA-N 0.000 description 1
- SHAPTWUCHCLTOX-UHFFFAOYSA-N CC(C)(C)c(cc1)ccc1S(Nc1cc(C)n[n]1-c1c(cccc2)c2cnc1)(=O)=O Chemical compound CC(C)(C)c(cc1)ccc1S(Nc1cc(C)n[n]1-c1c(cccc2)c2cnc1)(=O)=O SHAPTWUCHCLTOX-UHFFFAOYSA-N 0.000 description 1
- YUAYEJLDZQGHMM-UHFFFAOYSA-N CC(C)(C)c(cc1)ccc1S(Nc1cc(C)n[n]1-c1c(cccc2)c2cnn1)(=O)=O Chemical compound CC(C)(C)c(cc1)ccc1S(Nc1cc(C)n[n]1-c1c(cccc2)c2cnn1)(=O)=O YUAYEJLDZQGHMM-UHFFFAOYSA-N 0.000 description 1
- ZLFYHADDBSGSTC-UHFFFAOYSA-N CC(C)(C)c(cc1)ccc1S(Nc1cc(C)n[n]1-c1c(cccc2)c2nc(C)c1)(=O)=O Chemical compound CC(C)(C)c(cc1)ccc1S(Nc1cc(C)n[n]1-c1c(cccc2)c2nc(C)c1)(=O)=O ZLFYHADDBSGSTC-UHFFFAOYSA-N 0.000 description 1
- YHWOIOUUEZSCHD-UHFFFAOYSA-N CC(C)(C)c(cc1)ccc1S(Nc1cc(C)n[n]1-c1c(cccc2)c2nnc1)(=O)=O Chemical compound CC(C)(C)c(cc1)ccc1S(Nc1cc(C)n[n]1-c1c(cccc2)c2nnc1)(=O)=O YHWOIOUUEZSCHD-UHFFFAOYSA-N 0.000 description 1
- IJGGUPSGAGRQLD-UHFFFAOYSA-N CC(C)(C)c(cc1)ccc1S(Nc1cc(C)n[n]1-c1c(cccc2F)c2ncc1)(=O)=O Chemical compound CC(C)(C)c(cc1)ccc1S(Nc1cc(C)n[n]1-c1c(cccc2F)c2ncc1)(=O)=O IJGGUPSGAGRQLD-UHFFFAOYSA-N 0.000 description 1
- FCLSQIPBHRVDGN-UHFFFAOYSA-N CC(C)(C)c(cc1)ccc1S(Nc1cc(C)n[n]1-c1c(cccn2)c2c(C)cc1)(=O)=O Chemical compound CC(C)(C)c(cc1)ccc1S(Nc1cc(C)n[n]1-c1c(cccn2)c2c(C)cc1)(=O)=O FCLSQIPBHRVDGN-UHFFFAOYSA-N 0.000 description 1
- GHMJTJAOJBXGMT-UHFFFAOYSA-N CC(C)(C)c(cc1)ccc1S(Nc1cc(C)n[n]1-c1c(ccnc2N)c2ccc1)(=O)=O Chemical compound CC(C)(C)c(cc1)ccc1S(Nc1cc(C)n[n]1-c1c(ccnc2N)c2ccc1)(=O)=O GHMJTJAOJBXGMT-UHFFFAOYSA-N 0.000 description 1
- AYKLORYDFRQVLL-UHFFFAOYSA-N CC(C)(C)c(cc1)ccc1S(Nc1cc(C)n[n]1-c1cc(N)nc2c1cccc2)(=O)=O Chemical compound CC(C)(C)c(cc1)ccc1S(Nc1cc(C)n[n]1-c1cc(N)nc2c1cccc2)(=O)=O AYKLORYDFRQVLL-UHFFFAOYSA-N 0.000 description 1
- YEEOFIWJXIHPTE-UHFFFAOYSA-N CC(C)(C)c(cc1)ccc1S(Nc1cc(C)n[n]1-c1cc2ccccc2cc1)(=O)=O Chemical compound CC(C)(C)c(cc1)ccc1S(Nc1cc(C)n[n]1-c1cc2ccccc2cc1)(=O)=O YEEOFIWJXIHPTE-UHFFFAOYSA-N 0.000 description 1
- UVWBFPBIYXQAQY-UHFFFAOYSA-N CC(C)(C)c(cc1)ccc1S(Nc1cc(C)n[n]1-c1cc2ccccc2cn1)(=C)=O Chemical compound CC(C)(C)c(cc1)ccc1S(Nc1cc(C)n[n]1-c1cc2ccccc2cn1)(=C)=O UVWBFPBIYXQAQY-UHFFFAOYSA-N 0.000 description 1
- UDHGVXOFVDUESS-UHFFFAOYSA-N CC(C)(C)c(cc1)ccc1S(Nc1cc(C)n[n]1-c1cccc2c1ccnc2)(=O)=O Chemical compound CC(C)(C)c(cc1)ccc1S(Nc1cc(C)n[n]1-c1cccc2c1ccnc2)(=O)=O UDHGVXOFVDUESS-UHFFFAOYSA-N 0.000 description 1
- JRTHCZPFQPXUPS-UHFFFAOYSA-N CC(C)(C)c(cc1)ccc1S(Nc1ccn[n]1-c1c(cccn2)c2ccc1)(=O)=O Chemical compound CC(C)(C)c(cc1)ccc1S(Nc1ccn[n]1-c1c(cccn2)c2ccc1)(=O)=O JRTHCZPFQPXUPS-UHFFFAOYSA-N 0.000 description 1
- LEJAKOZBYWCWIS-UHFFFAOYSA-N CC(C)(C)c(cc1F)ccc1S(Nc1cc(C)n[n]1-c1c(cccn2)c2ccc1)(=O)=O Chemical compound CC(C)(C)c(cc1F)ccc1S(Nc1cc(C)n[n]1-c1c(cccn2)c2ccc1)(=O)=O LEJAKOZBYWCWIS-UHFFFAOYSA-N 0.000 description 1
- GWDDVYUGVUJLHI-UHFFFAOYSA-N CC(C)(C)c(ccc(S(Nc1cc(C(F)F)n[n]1-c1c(cccn2)c2ccc1)(=O)=O)c1)c1F Chemical compound CC(C)(C)c(ccc(S(Nc1cc(C(F)F)n[n]1-c1c(cccn2)c2ccc1)(=O)=O)c1)c1F GWDDVYUGVUJLHI-UHFFFAOYSA-N 0.000 description 1
- DMBYVPJRFYFHOU-UHFFFAOYSA-N CC(C)(C)c(ccc(S(Nc1cc(C)n[n]1-c1c(cccn2)c2ccc1)(=O)=O)c1)c1Cl Chemical compound CC(C)(C)c(ccc(S(Nc1cc(C)n[n]1-c1c(cccn2)c2ccc1)(=O)=O)c1)c1Cl DMBYVPJRFYFHOU-UHFFFAOYSA-N 0.000 description 1
- SHLXDRIRXFOWJL-UHFFFAOYSA-N CC(C)COc(cc1)ccc1S(Nc1cc(C)n[n]1-c1c(cccn2)c2ccc1)(=O)=O Chemical compound CC(C)COc(cc1)ccc1S(Nc1cc(C)n[n]1-c1c(cccn2)c2ccc1)(=O)=O SHLXDRIRXFOWJL-UHFFFAOYSA-N 0.000 description 1
- HUHNKSIOENDROI-UHFFFAOYSA-N CC(C)Oc(cc1)ccc1S(Nc1cc(C(F)(F)F)n[n]1-c1c(cccn2)c2ccc1)(=O)=O Chemical compound CC(C)Oc(cc1)ccc1S(Nc1cc(C(F)(F)F)n[n]1-c1c(cccn2)c2ccc1)(=O)=O HUHNKSIOENDROI-UHFFFAOYSA-N 0.000 description 1
- NLTXIULBNZDIGK-UHFFFAOYSA-N CC(C)Oc(cc1)ccc1S(Nc1cc(C(F)(F)F)n[n]1-c1c(ccnc2)c2ccc1)(=O)=O Chemical compound CC(C)Oc(cc1)ccc1S(Nc1cc(C(F)(F)F)n[n]1-c1c(ccnc2)c2ccc1)(=O)=O NLTXIULBNZDIGK-UHFFFAOYSA-N 0.000 description 1
- UDYPCDHSTZIIKE-UHFFFAOYSA-N CC(C)Oc(cc1)ccc1S(Nc1cc(C(F)F)n[n]1-c1c(cccn2)c2ccc1)(=O)=O Chemical compound CC(C)Oc(cc1)ccc1S(Nc1cc(C(F)F)n[n]1-c1c(cccn2)c2ccc1)(=O)=O UDYPCDHSTZIIKE-UHFFFAOYSA-N 0.000 description 1
- IRMSKGAADUJRGP-UHFFFAOYSA-N CC(C)Oc(cc1)ccc1S(Nc1cc(C)n[n]1-c1c(cccn2)c2ccc1)(=O)=O Chemical compound CC(C)Oc(cc1)ccc1S(Nc1cc(C)n[n]1-c1c(cccn2)c2ccc1)(=O)=O IRMSKGAADUJRGP-UHFFFAOYSA-N 0.000 description 1
- BTFZFBKXNHFRRI-UHFFFAOYSA-N CC(C)Oc(cc1)ccc1S(Nc1cc(C)n[n]1-c1c(ccnc2)c2ccc1)(=O)=O Chemical compound CC(C)Oc(cc1)ccc1S(Nc1cc(C)n[n]1-c1c(ccnc2)c2ccc1)(=O)=O BTFZFBKXNHFRRI-UHFFFAOYSA-N 0.000 description 1
- PFIULKICYHTRLM-UHFFFAOYSA-N CC(C)Oc(cc1)ccc1S(Nc1cc(CF)n[n]1-c1c(cccn2)c2ccc1)(=O)=O Chemical compound CC(C)Oc(cc1)ccc1S(Nc1cc(CF)n[n]1-c1c(cccn2)c2ccc1)(=O)=O PFIULKICYHTRLM-UHFFFAOYSA-N 0.000 description 1
- UWKIBDVOGPRZLT-UHFFFAOYSA-N CC(C)c(cc1)ccc1S(Nc1cc(C(F)(F)F)n[n]1-c1c(ccnc2)c2ccc1)(=O)=O Chemical compound CC(C)c(cc1)ccc1S(Nc1cc(C(F)(F)F)n[n]1-c1c(ccnc2)c2ccc1)(=O)=O UWKIBDVOGPRZLT-UHFFFAOYSA-N 0.000 description 1
- HCDLXHKEODDCQG-UHFFFAOYSA-N CC(C)c(cc1)ccc1S(Nc1cc(C(F)F)n[n]1-c1c(cccn2)c2ccc1)(=O)=O Chemical compound CC(C)c(cc1)ccc1S(Nc1cc(C(F)F)n[n]1-c1c(cccn2)c2ccc1)(=O)=O HCDLXHKEODDCQG-UHFFFAOYSA-N 0.000 description 1
- VRLPRXXRGWMKHJ-UHFFFAOYSA-N CC(C)c(cc1)ccc1S(Nc1cc(C)n[n]1-c1c(cccn2)c2ccc1)(=O)=O Chemical compound CC(C)c(cc1)ccc1S(Nc1cc(C)n[n]1-c1c(cccn2)c2ccc1)(=O)=O VRLPRXXRGWMKHJ-UHFFFAOYSA-N 0.000 description 1
- IGSKPFIUXLOGFR-UHFFFAOYSA-N CC(C)c(cc1)ccc1S(Nc1cc(C)n[n]1-c1c(ccnc2)c2ccc1)(=O)=O Chemical compound CC(C)c(cc1)ccc1S(Nc1cc(C)n[n]1-c1c(ccnc2)c2ccc1)(=O)=O IGSKPFIUXLOGFR-UHFFFAOYSA-N 0.000 description 1
- YLZDDZQXQPEMGI-UHFFFAOYSA-N CC1(C)Oc2ccc(CCNc3cc(C)n[n]3-c3c(cccn4)c4ccc3)cc2CC1 Chemical compound CC1(C)Oc2ccc(CCNc3cc(C)n[n]3-c3c(cccn4)c4ccc3)cc2CC1 YLZDDZQXQPEMGI-UHFFFAOYSA-N 0.000 description 1
- PPFXTLNINFIPJZ-UHFFFAOYSA-N CCC(C)(C)c(cc1)ccc1S(Nc1cc(C)n[n]1-c1c(cccn2)c2ccc1)(=O)=O Chemical compound CCC(C)(C)c(cc1)ccc1S(Nc1cc(C)n[n]1-c1c(cccn2)c2ccc1)(=O)=O PPFXTLNINFIPJZ-UHFFFAOYSA-N 0.000 description 1
- DPNWUMBKCGKXDQ-UHFFFAOYSA-N Cc(cc1NS(c(cc2)ccc2OC(F)(F)F)(=O)=O)n[n]1-c1c(cccn2)c2ccc1 Chemical compound Cc(cc1NS(c(cc2)ccc2OC(F)(F)F)(=O)=O)n[n]1-c1c(cccn2)c2ccc1 DPNWUMBKCGKXDQ-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462060454P | 2014-10-06 | 2014-10-06 | |
| US62/060,454 | 2014-10-06 | ||
| PCT/US2015/054077 WO2016057424A1 (en) | 2014-10-06 | 2015-10-05 | Combination therapy of inhibitors of c-c chemokine receptor type 9 (ccr9) and anti-alha4beta7 integrin blocking antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020082164A Division JP7025781B2 (ja) | 2014-10-06 | 2020-05-07 | ＣＣケモカイン受容体９（ＣＣＲ９）の阻害剤と抗α４β７インテグリン遮断抗体の併用療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017530163A JP2017530163A (ja) | 2017-10-12 |
| JP2017530163A5 true JP2017530163A5 (enExample) | 2019-02-07 |
| JP6954834B2 JP6954834B2 (ja) | 2021-10-27 |
Family
ID=55632011
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017518197A Active JP6954834B2 (ja) | 2014-10-06 | 2015-10-05 | ＣＣケモカイン受容体９（ＣＣＲ９）の阻害剤と抗α４β７インテグリン遮断抗体の併用療法 |
| JP2020082164A Active JP7025781B2 (ja) | 2014-10-06 | 2020-05-07 | ＣＣケモカイン受容体９（ＣＣＲ９）の阻害剤と抗α４β７インテグリン遮断抗体の併用療法 |
| JP2022016197A Pending JP2022051829A (ja) | 2014-10-06 | 2022-02-04 | ＣＣケモカイン受容体９（ＣＣＲ９）の阻害剤と抗α４β７インテグリン遮断抗体の併用療法 |
| JP2024066342A Pending JP2024094370A (ja) | 2014-10-06 | 2024-04-16 | ＣＣケモカイン受容体９（ＣＣＲ９）の阻害剤と抗α４β７インテグリン遮断抗体の併用療法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020082164A Active JP7025781B2 (ja) | 2014-10-06 | 2020-05-07 | ＣＣケモカイン受容体９（ＣＣＲ９）の阻害剤と抗α４β７インテグリン遮断抗体の併用療法 |
| JP2022016197A Pending JP2022051829A (ja) | 2014-10-06 | 2022-02-04 | ＣＣケモカイン受容体９（ＣＣＲ９）の阻害剤と抗α４β７インテグリン遮断抗体の併用療法 |
| JP2024066342A Pending JP2024094370A (ja) | 2014-10-06 | 2024-04-16 | ＣＣケモカイン受容体９（ＣＣＲ９）の阻害剤と抗α４β７インテグリン遮断抗体の併用療法 |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US10532051B2 (enExample) |
| EP (2) | EP4268820A3 (enExample) |
| JP (4) | JP6954834B2 (enExample) |
| KR (3) | KR20240033093A (enExample) |
| CN (1) | CN107001467A (enExample) |
| AU (1) | AU2015328396B2 (enExample) |
| CA (2) | CA3224013A1 (enExample) |
| ES (1) | ES2971041T3 (enExample) |
| IL (2) | IL251136B (enExample) |
| MA (1) | MA40592A (enExample) |
| MX (2) | MX2017004344A (enExample) |
| NZ (1) | NZ768528A (enExample) |
| RU (1) | RU2713653C2 (enExample) |
| SG (1) | SG11201702793XA (enExample) |
| WO (1) | WO2016057424A1 (enExample) |
| ZA (1) | ZA201701852B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201405241VA (en) * | 2012-02-29 | 2014-09-26 | Chemocentryx Inc | Pyrazol-1-yl benzene sulfonamides as ccr9 antagonists |
| MA40592A (fr) * | 2014-10-06 | 2016-04-14 | Chemocentryx Inc | Compositions et méthodes pour le traitement d'une maladie inflammatoire de l'intestin à l'aide d'une polythérapie à base d'inhibiteurs à petites molécules de récepteur 9 de chimiokine c-c (ccr9) et d'anticorps bloquants anti-intégrine alpha4beta7 |
| EP3552632B1 (en) * | 2016-12-07 | 2023-07-12 | Stelic Institute & Co., Inc. | Medicinal composition for treating and preventing inflammatory bowel disease |
| US20210154292A1 (en) * | 2019-11-21 | 2021-05-27 | Chemocentryx, Inc. | Compositions and Methods for Treating CCR9-Mediated Diseases using CCR9 Inhibitor and Anti-TNF-Alpha Blocking Antibodies |
| WO2021174024A1 (en) | 2020-02-28 | 2021-09-02 | First Wave Bio, Inc. | Methods of treating iatrogenic autoimmune colitis |
| WO2021202731A1 (en) | 2020-03-31 | 2021-10-07 | Chemocentryx, Inc. | Compositions and methods for treating inflammatory bowel disease using ccr9 inhibitor and anti-il-23 blocking antibodies |
| CN114314701B (zh) * | 2021-11-30 | 2023-10-20 | 昆明贵研药业有限公司 | 一种三氯氨铂酸钾的制备方法及其在制备顺式-氨-水-铂配合物中的应用 |
| AU2024282654A1 (en) | 2023-05-30 | 2025-12-04 | Paragon Therapeutics, Inc. | Alpha4beta7 integrin antibody compositions and methods of use |
| WO2025177214A1 (en) * | 2024-02-20 | 2025-08-28 | Takeda Pharmaceutical Company Limited | Therapeutic methods |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
| US5120643A (en) | 1987-07-13 | 1992-06-09 | Abbott Laboratories | Process for immunochromatography with colloidal particles |
| US6159686A (en) | 1992-09-14 | 2000-12-12 | Sri International | Up-converting reporters for biological and other assays |
| US7147851B1 (en) | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
| US6322901B1 (en) | 1997-11-13 | 2001-11-27 | Massachusetts Institute Of Technology | Highly luminescent color-selective nano-crystalline materials |
| US6207392B1 (en) | 1997-11-25 | 2001-03-27 | The Regents Of The University Of California | Semiconductor nanocrystal probes for biological applications and process for making and using such probes |
| US5990479A (en) | 1997-11-25 | 1999-11-23 | Regents Of The University Of California | Organo Luminescent semiconductor nanocrystal probes for biological applications and process for making and using such probes |
| US6306610B1 (en) | 1998-09-18 | 2001-10-23 | Massachusetts Institute Of Technology | Biological applications of quantum dots |
| US6251303B1 (en) | 1998-09-18 | 2001-06-26 | Massachusetts Institute Of Technology | Water-soluble fluorescent nanocrystals |
| US6326144B1 (en) | 1998-09-18 | 2001-12-04 | Massachusetts Institute Of Technology | Biological applications of quantum dots |
| WO2002000651A2 (en) | 2000-06-27 | 2002-01-03 | Bristol-Myers Squibb Pharma Company | Factor xa inhibitors |
| US6451399B1 (en) | 2001-02-05 | 2002-09-17 | Daniel G. Boyce | Display mat |
| MXPA04011465A (es) | 2002-05-24 | 2005-02-14 | Millennium Pharm Inc | Inhibidores de ccr9 y metodos de uso de los mismos. |
| US7741519B2 (en) | 2007-04-23 | 2010-06-22 | Chemocentryx, Inc. | Bis-aryl sulfonamides |
| ATE517102T1 (de) | 2002-11-18 | 2011-08-15 | Chemocentryx Inc | Arylsulfonamide |
| US7420055B2 (en) | 2002-11-18 | 2008-09-02 | Chemocentryx, Inc. | Aryl sulfonamides |
| TW200510311A (en) | 2002-12-23 | 2005-03-16 | Millennium Pharm Inc | CCr8 inhibitors |
| SE0301653D0 (sv) | 2003-06-05 | 2003-06-05 | Astrazeneca Ab | Novel compounds |
| JP2007537275A (ja) | 2004-05-12 | 2007-12-20 | ケモセントリックス， インコーポレイテッド | アリールスルホンアミド |
| SE0402635D0 (sv) | 2004-10-29 | 2004-10-29 | Astrazeneca Ab | Chemical compounds |
| US7622583B2 (en) | 2005-01-14 | 2009-11-24 | Chemocentryx, Inc. | Heteroaryl sulfonamides and CCR2 |
| US20120283411A9 (en) | 2006-06-29 | 2012-11-08 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| ES2360741T3 (es) | 2006-07-14 | 2011-06-08 | Chemocentryx, Inc. | Triazolil fenil bencenosulfonamidas. |
| WO2008008374A2 (en) | 2006-07-14 | 2008-01-17 | Chemocentryx, Inc. | Ccr2 inhibitors and methods of use thereof |
| US7718683B2 (en) | 2006-07-14 | 2010-05-18 | Chemocentryx, Inc. | Triazolyl phenyl benzenesulfonamides |
| TW200831528A (en) * | 2006-11-30 | 2008-08-01 | Astrazeneca Ab | Compounds |
| CA2676145A1 (en) | 2007-02-06 | 2008-08-14 | Novartis Ag | 1-benzenesulfonyl-1h-indole derivatives as inhibitors of ccr9 activity |
| US7776877B2 (en) | 2007-06-22 | 2010-08-17 | Chemocentryx, Inc. | N-(2-(hetaryl)aryl) arylsulfonamides and N-(2-(hetaryl) hetaryl arylsulfonamides |
| US9315449B2 (en) | 2008-05-15 | 2016-04-19 | Duke University | Substituted pyrazoles as heat shock transcription factor activators |
| NZ595464A (en) | 2009-03-20 | 2013-08-30 | Amgen Inc | Alpha-4-beta-7 heterodimer specific antagonist antibody |
| SMT201700515T1 (it) | 2011-05-02 | 2018-01-11 | Millennium Pharm Inc | Formulazione per anticorpo anti- 4 7 |
| UA116189C2 (uk) * | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
| CA2842753A1 (en) | 2011-07-22 | 2013-01-31 | Chemocentryx, Inc. | Polymorphic forms of the sodium salt of 4-tert-butyl-n-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide |
| ES2625286T3 (es) | 2011-07-22 | 2017-07-19 | Chemocentryx, Inc. | Una forma cristalina de la sal sódica de 4-terc-butil-n-[4-cloro-2-(1-oxi-piridin-4-carbonil)-fenil]-bencenosulfonamida |
| WO2013016155A1 (en) | 2011-07-22 | 2013-01-31 | Glaxo Group Limited | Polymorphic forms of the sodium salt of 4-tert-butyl-n-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide |
| SG11201405241VA (en) | 2012-02-29 | 2014-09-26 | Chemocentryx Inc | Pyrazol-1-yl benzene sulfonamides as ccr9 antagonists |
| MA40592A (fr) * | 2014-10-06 | 2016-04-14 | Chemocentryx Inc | Compositions et méthodes pour le traitement d'une maladie inflammatoire de l'intestin à l'aide d'une polythérapie à base d'inhibiteurs à petites molécules de récepteur 9 de chimiokine c-c (ccr9) et d'anticorps bloquants anti-intégrine alpha4beta7 |
-
2015
- 2015-10-05 MA MA040592A patent/MA40592A/fr unknown
- 2015-10-05 AU AU2015328396A patent/AU2015328396B2/en active Active
- 2015-10-05 CA CA3224013A patent/CA3224013A1/en active Pending
- 2015-10-05 ES ES15848916T patent/ES2971041T3/es active Active
- 2015-10-05 SG SG11201702793XA patent/SG11201702793XA/en unknown
- 2015-10-05 IL IL251136A patent/IL251136B/en unknown
- 2015-10-05 CA CA2960876A patent/CA2960876C/en active Active
- 2015-10-05 EP EP23197483.3A patent/EP4268820A3/en active Pending
- 2015-10-05 KR KR1020247006273A patent/KR20240033093A/ko not_active Ceased
- 2015-10-05 JP JP2017518197A patent/JP6954834B2/ja active Active
- 2015-10-05 US US14/875,506 patent/US10532051B2/en active Active
- 2015-10-05 KR KR1020177012272A patent/KR102514565B1/ko active Active
- 2015-10-05 WO PCT/US2015/054077 patent/WO2016057424A1/en not_active Ceased
- 2015-10-05 NZ NZ768528A patent/NZ768528A/en unknown
- 2015-10-05 CN CN201580054158.XA patent/CN107001467A/zh active Pending
- 2015-10-05 IL IL292655A patent/IL292655B2/en unknown
- 2015-10-05 RU RU2017115809A patent/RU2713653C2/ru active
- 2015-10-05 KR KR1020237009744A patent/KR102642382B1/ko active Active
- 2015-10-05 MX MX2017004344A patent/MX2017004344A/es unknown
- 2015-10-05 EP EP15848916.1A patent/EP3204424B1/en active Active
-
2017
- 2017-03-15 ZA ZA2017/01852A patent/ZA201701852B/en unknown
- 2017-04-03 MX MX2022008951A patent/MX2022008951A/es unknown
-
2019
- 2019-12-09 US US16/708,167 patent/US11020394B2/en active Active
-
2020
- 2020-05-07 JP JP2020082164A patent/JP7025781B2/ja active Active
- 2020-05-14 US US15/929,647 patent/US11045469B2/en active Active
-
2021
- 2021-05-24 US US17/328,293 patent/US20210322410A1/en not_active Abandoned
-
2022
- 2022-02-04 JP JP2022016197A patent/JP2022051829A/ja active Pending
-
2024
- 2024-04-16 JP JP2024066342A patent/JP2024094370A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017530163A5 (enExample) | ||
| JP2023098947A5 (enExample) | ||
| IL273188B (en) | Treatment with a combination of chemokine receptor 2 (ccr2) inhibitors and a pd-1/pd-l1 inhibitor | |
| IL292655A (en) | Combination therapy of inhibitors of c-c chemokine receptor type 9 (ccr9) and anti-alha4beta7 integrin blocking antibodies | |
| HRP20240817T1 (hr) | Kombinirana terapija koja sadrži ivosidenib, citarabin i daunorubicin ili idarubicin za liječenje akutne mijelogene leukemije | |
| JP2013507439A5 (enExample) | ||
| JP2015529225A5 (enExample) | ||
| HRP20250119T1 (hr) | Kdm1a inhibitor i njegova primjena u terapiji | |
| RU2018138828A (ru) | Уменьшение массы опухоли путем введения ccr1 антагонистов в комбинации с pd-1 ингибиторами или pd-l1 ингибиторами | |
| JP2019510832A5 (enExample) | ||
| RU2017127135A (ru) | Терапевтическое средство против рака желчных протоков | |
| JP2014521735A5 (enExample) | ||
| HRP20201916T1 (hr) | Trifluorometil supstituirani pirazoli kao inhibitori kalikreina u ljudskoj plazmi | |
| JP2015511638A5 (enExample) | ||
| JP2013542261A5 (enExample) | ||
| JP2014533279A5 (enExample) | ||
| HRP20191617T1 (hr) | Kombinacija koja sadrži inhibitor mek i inhibitor b-raf | |
| JP2012525393A5 (enExample) | ||
| JP2014526503A5 (enExample) | ||
| JP2014510729A5 (enExample) | ||
| JP2015526459A5 (enExample) | ||
| JP2017522273A5 (enExample) | ||
| JP2012193216A5 (enExample) | ||
| JP2017524735A5 (enExample) | ||
| JP2024094370A5 (enExample) |